Advertisement

Topics

Sanofi gets BTK inhibitor for MS from Principia

14:40 EST 10 Nov 2017 | Elsevier Business Intelligence

Principia Biopharma Inc. granted Sanofi exclusive global rights to develop and sell its Bruton’s kinase inhibitor PRN2246 f...

Original Article: Sanofi gets BTK inhibitor for MS from Principia

NEXT ARTICLE

More From BioPortfolio on "Sanofi gets BTK inhibitor for MS from Principia"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Multiple Sclerosis MS
Multiple sclerosis (MS) is the most common disabling neurological condition affecting 100,000 young adults in the UK. The condition results from autoimmune damage to myelin, causing interference in nerve signaling. Symptoms experienced depend on the pa...